ArticleNaunyn-Schmiedeberg's archives of pharmacology2021
Amelioration of autoimmunity and inflammation by zinc oxide nanoparticles in experimental rheumatoid arthritis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- MSC Exosomes and Rutin-Chitosan-Pectin Nanoparticles Synergize to Ameliorate Adjuvant Arthritis via Th1/Th2 Modulation, MMP Suppression, Nrf2 Upregulation, and Antioxidant Boost.Stem cells international · 2026Article
- Trace Elements-Role in Joint Function and Impact on Joint Diseases.International journal of molecular sciences · 2025Review
- Multiscale metal-based nanocomposites for bone and joint disease therapies.Materials today. Bio · 2025Review
- Dapagliflozin targets the crosstalk between apoptosis, autophagy, and Hedgehog signaling pathways through AMPK activation in the adjuvant-induced arthritic rat model.Inflammopharmacology · 2025Article
- The association between dietary zinc intake and osteopenia, osteoporosis in patients with rheumatoid arthritis.BMC musculoskeletal disorders · 2024Article
- Enhanced Wound Healing With β-Chitosan-Zinc Oxide Nanoparticles: Insights From Zebrafish Models.Cureus · 2024Article
- Comparative effects of dietary zinc nanoparticle and conventional zinc supplementation on broiler chickens: A meta-analysis.Veterinary world · 2024Article
- Assessing the Impact of Influenza Vaccination Timing on Experimental Arthritis: Effects on Disease Progression and Inflammatory Biomarkers.International journal of molecular sciences · 2024Article
- Zinc oxide nanoparticles-doped curcumin-assisted recovery of rheumatoid arthritis and antioxidant status in experimental rabbits.BioMedicine · 2024Article
- Recent Advances in ZnO Nanomaterial-Mediated Biological Applications and Action Mechanisms.Nanomaterials (Basel, Switzerland) · 2023Review
- Effect of Two Particle Sizes of Nano Zinc Oxide on Growth Performance, Immune Function, Digestive Tract Morphology, and Intestinal Microbiota Composition in Broilers.Animals : an open access journal from MDPI · 2023Article
- Fly Me to the Immune: Immunonutrition in Rheumatic Diseases.Mediterranean journal of rheumatology · 2023Article
- Therapeutic Potential of Zeolites/Vitamin B12 Nanocomposite on Complete Freund's Adjuvant-Induced Arthritis as a Bone Disorder: In Vivo Study and Bio-Molecular Investigations.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Novel anti-arthritic mechanisms of trans-cinnamaldehyde against complete Freund's adjuvant-induced arthritis in mice: involvement of NF-кB/TNF-α and IL-6/IL-23/ IL-17 pathways in the immuno-inflammatory responses.Inflammopharmacology · 2022Article
- Diosmin and Trolox Have Anti-Arthritic, Anti-Inflammatory and Antioxidant Potencies in Complete Freund's Adjuvant-Induced Arthritic Male Wistar Rats: Roles of NF-κB, iNOS, Nrf2 and MMPs.Antioxidants (Basel, Switzerland) · 2022Article
- Dose-Dependent Efficacy of Umbelliferone and Gelatin-Coated ZnO/ZnS Core-Shell Nanoparticles: A Novel Arthritis Agent for Severe Knee Arthritis.Oxidative medicine and cellular longevity · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the lining of the synovial joints and approximately affects 0.5 - 1% of the total population imposing a socioeconomic burden. The current study aimed at investigating the novel possible beneficial effects of using zinc oxide nanoparticles (ZnO NPs) on such devastating disease. The complete Freund's adjuvant (CFA) model was used to mimic RA in rats where ZnO NPs were given orally (2 mg/kg/day) daily for 14 days; and diclofenac Na, the standard drug, was given intraperitoneally (1 mg/kg/day) the day after CFA, daily for 14 days. Our results displayed that ZnO NPs attenuated adjuvant-induced increased production of inflammatory mediators interleukin-1β (IL-1β), tumor necrosis factor alpha (TNF-α), interleukin-10 (IL-10), and total leukocyte count. Besides, they ameliorated autoimmunity through suppression of anti-citrullinated protein auto antibodies (anti-CCP) levels in rats. In conclusion our results highlight the benefits which could be obtained of nanoparticles either alone or in combination with the known anti-arthritic and/or anti-inflammatory agents, giving rise to new protocols to maximize the control of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.